Independent Pharmacies Embracing Pharmacogenetics
RENO, Nev. — According to the Centers for Disease Control (CDC), 82% of American adults take at least one medication and 29% take five or more. In addition, the CDC reports over 2 million adverse drug reactions each year leading to emergency room visits, with an estimated 100,000 deaths annually.
In response to this serious health issue,Cardinal Health announced that it has chosen the Rxight® (pronounced “RIGHT”) pharmacogenetic program to feature in their exclusive Showcase Area during their 2018 RBC conference being held in San Diego June 27-30. The Rxight program helps determine if the medications people take and the dosage levels are right for them based on their DNA. Rxight provides medication guidance on over 230 prescription and OTC medications.
“Cardinal Health recognizes the importance of pharmacogenetics and the role of pharmacists in helping their providers make more informed prescribing decisions to help achieve desired outcomes sooner and avoid adverse effects,” said Chuck Dushman, Vice President of Marketing for MD Labs. “Cardinal is now making it easier for pharmacies to incorporate pharmacogenetics.”
Pharmacogenetics uses information about a person’s genetic profile to help choose the medication and drug doses that are likely to work best for them, helping to avoid ineffective or potentially dangerous drug reactions. After their provider has authorized the lab test, the patient visits a pharmacy for a simple cheek swab and to purchase the Rxight test. The pharmacist receives the results from the lab within 7 business days. Each patient receives their results during a Personalized Medication Review with a pharmacist trained in pharmacogenetics. The pharmacist will then coordinate care with the patient’s provider.
The Rxight test provides information on medications covering 50 therapeutic classes, including blood pressure, cholesterol, blood thinners, other heart issues, ADHD, anxiety, depression, diabetes, pain, ED, acid reflux, oncology and more. It is highly likely that someone is taking one of these medications now or will need to take them in the future.
“Being featured by Cardinal as their pharmacogenetics program of choice for their thousands of national physician and pharmacy customers is a great way to grow the awareness and availability of this life-saving technology,” said Matthew Rutledge, co-founder of MD Labs. “Together we will help pharmacists bring the promise of precision medicine to their communities.”
To learn more about the Rxight test and to learn how you can provide pharmacogenetics to your patients, visit the Rxight booth in the RBC Showcase area or contact the Rxight team at info@Rxight.com/ 888-888-1932.
About MD Labs and Rxight
Developed by MD Labs, a leading high-complexity CLIA certified laboratory specializing in clinical lab testing, Rxight is the leading pharmacogenetic program used by pharmacists. Founded in 2011, MD Labs serves healthcare providers across the United States with state-of-the-art technology and testing for a wide array of analytes. Their team of PhDs and clinical technologists are able to keep ahead of the needs of the medical community. To learn more, please visit Rxight.com.
About Cardinal Health
Cardinal Health, Inc. is a global, integrated healthcare services and products company, providing customized solutions for hospitals, healthcare systems, pharmacies, ambulatory surgery centers, clinical laboratories and physician offices worldwide. The company provides clinically proven medical products, pharmaceuticals and cost-effective solutions that enhance supply chain efficiency from hospital to home. Cardinal Health connects patients, providers, payers, pharmacists and manufacturers for integrated care coordination and better patient management. For more information, visit cardinalhealth.com.